Clinical trials: Progesterone
Breast Cancer
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
RATIONALE: Panobinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of breast cancer cells.
- Trial name
- NCT01105312
- Testing
- letrozole, panobinostat, RNA analysis
- Where
- 172 sites in United States
- Volunteers
- 28 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
Preoperative Cisplatin and Bevacizumab in ER-, PR-, HER2 Negative Breast Cancer
The purpose of this study is to find out what effect taking cisplatin in combination with bevacizumab before surgery and then standard chemotherapy plus bevacizumab after surgery will have on participants with Estrogen Receptor…
- Trial name
- NCT00580333
- Testing
- cisplatin, bevacizumab, doxorubicin
- Where
- 3 sites in United States
- Volunteers
- 51 people
- Sponsor
- Massachusetts General Hospital
Hypothalamic-pituitary-ovarian Axis, Gonadotropins, Ethinyl Estradiol, Contraceptive Efficacy
Oral Contraceptive Hormone-free Interval Pituitary/ Ovarian Activity
The degree of suppression and subsequent activation of the hypothalamic-pituitary-ovarian axis during the hormone-free interval in combined oral contraceptive (COC) hormone users varies depending on the dose of ethinyl estradiol…
- Trial name
- NCT01953211
- Testing
- combined oral contraceptives
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- University of Southern California
Her2 Negative Breast Cancer Patients
Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer
To determine whether the combination MM-121 + Exemestane in ER+ and/or PR+ breast cancer patients is more effective than Exemestane alone
- Trial name
- NCT01151046
- Testing
- MM-121, Exemestane
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 118 people
- Sponsor
- Merrimack Pharmaceuticals
Cannabis Use Disorder, Cannabis Withdrawal
Progesterone for Cannabis Withdrawal
Sex and gender differences in behavioral, biological, and clinical correlates of substance use disorders are myriad, yet there exists a dearth of gender-informed treatment options.
- Trial name
- NCT03430050
- Testing
- Progesterone
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Medical University of South Carolina
Preterm Birth
17OHP for Reduction of Neonatal Morbidity Due to Preterm Birth (PTB) in Twin and Triplet Pregnancies
Hypothesis: Among women with twin or triplet pregnancies, weekly injections of 17-alpha-hydroxyprogesterone caproate (17OHP), started before 24 weeks of gestation, will reduce neonatal morbidity by reducing the rate of preterm…
- Trial name
- 170HP (NCT00163020)
- Testing
- 17-alpha-hydroxyprogesterone caproate injectable
- Where
- 18 sites in United States
- Volunteers
- 321 people
- Sponsor
- Obstetrix Medical Group
Preterm Delivery, Short Cervix
PREGNANT Short Cervix Trial
The purpose of this research study is to evaluate the usefulness of progesterone vaginal gel in decreasing the preterm birth rate in a population of pregnant women with short cervical length and at high risk for preterm birth.
- Conditions
- Preterm Delivery, Short Cervix, Short Uterine Cervical Length
- Trial name
- NCT00615550
- Testing
- progesterone
- Where
- 49 sites in United States, Belarus and 8 more
- Volunteers
- 465 people, healthy volunteers welcome
- Sponsor
- Juniper Pharmaceuticals, Inc.
Tobacco Use Cessation, Tobacco Use Disorder
Progesterone & Postpartum Relapse to Smoking
The primary goal of this project is to investigate the potential efficacy of exogenous progesterone (with supplemental relapse prevention counseling) on postpartum relapse in new mothers.
- Trial name
- NCT01798394
- Testing
- Progesterone
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Heavy Menstrual Bleeding
Quality of Life in Premenopausal Women With Heavy Menstrual Bleeding
Heavy menstrual bleeding or menorrhagia, is a common problem on women's lives and can burden both patients and health care systems. HMB is defined as cyclic heavy vaginal bleeding.
- Trial name
- NCT03368898
- Where
- Turkey (Türkiye)
- Volunteers
- 104 people
- Sponsor
- Bakirkoy Dr. Sadi Konuk Research and Training Hospital
Premenstrual Syndrome, Menstruation Disturbances
A Treatment Study for Premenstrual Syndrome (PMS)
This study examines the effects of estrogen and progesterone on mood, the stress response, and brain function and behavior in women with premenstrual syndrome.
- Trial name
- NCT00001259
- Testing
- Leuprolide, Estradiol Patches, Progesterone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Mental Health (NIMH)
Preterm Delivery, Cervical Length
RCT of Progesterone to Prevent Preterm Birth in Nulliparous Women With a Short Cervix
The purpose of this study is to see if giving progesterone medication to pregnant women, who have never delivered a baby after 19 weeks of pregnancy and who have a short cervix, lowers the risk of early delivery and improves the…
- Trial name
- SCAN (NCT00439374)
- Testing
- 17 alpha-hydroxyprogesterone caproate
- Where
- 14 sites in United States
- Volunteers
- 657 people, healthy volunteers welcome
- Sponsor
- The George Washington University Biostatistics Center
Leiomyoma
Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914
This study will evaluate whether the experimental drug ulipristal acetate can shrink uterine fibroids in pre-menopausal women.
- Trial name
- NCT00290251
- Testing
- ulipristal acetate 20 mg, ulipristal acetate 10 mg
- Where
- 2 sites in United States
- Volunteers
- 72 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Estrogen Receptor Negative, Estrogen Receptor Positive
Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
This phase II trial studies how well pembrolizumab and doxorubicin hydrochloride works compared to pembrolizumab with anti-estrogen therapy (anastrozole, letrozole, or exemestane) in treating patients with triple-negative or…
- Conditions
- Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative
- Trial name
- NCT02648477
- Testing
- Anastrozole, Doxorubicin Hydrochloride, Exemestane
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- City of Hope Medical Center
Smoking Cessation
Progesterone Augmentation of Nicotine Replacement Therapy Study
This will be a double-blind, placebo-controlled, pilot, randomized clinical trial. A total of 50 women who smoke and have regular menstrual cycles will be randomized to either progesterone (200 mgs BID) + Transdermal Nicotine…
- Trial name
- PANS (NCT02685072)
- Testing
- Progesterone (200 mgs BID)
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Yale University
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer
Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer
This phase II clinical trial studies how well gamma-secretase/Notch signalling pathway inhibitor RO4929097 works in treating patients with advanced, metastatic, or recurrent triple negative invasive breast cancer.
- Conditions
- Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Male Breast Cancer, Progesterone Receptor-negative Breast Cancer
- Trial name
- NCT01151449
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, laboratory biomarker analysis
- Where
- 2 sites in Canada
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Normal, PCOS
Determining How Quickly Progesterone Slows LH Pulse Frequency
The rapidity with which progesterone (P) suppresses daytime lutenizing hormone (LH) (and by inference gonadotropin releasing hormone (GnRH)) pulse frequency is unknown.
- Trial name
- CRM001 (NCT00594217)
- Testing
- oral micronized progesterone suspension
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer
Phase II Study of Everolimus Beyond Progression
This phase II trial studies how well everolimus and hormone therapy work in treating patients with hormone receptor positive breast cancer that has continued to spread (progressed) or returned after a period of improvement…
- Conditions
- Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT02269670
- Testing
- everolimus, anastrozole, letrozole
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- Emory University
Preterm Birth
Efficacy Study of a Cervical Pessary Containing Progesterone for the Prevention of Preterm Delivery
Assess the efficacy of 2 Cervical Pessaries containing 6.3 g and 7.7 g micronized progesterone for the prevention of preterm delivery, established through spontaneous birth before gestation weeks 32 (31 weeks and 6 days) and 34…
- Trial name
- PCP002 (NCT02225353)
- Testing
- Progesterone Cervical Pessary 6.3 g, Progesterone 200 mg vaginal capsules, Progesterone Cervical Pessary 7.7 g
- Where
- 4 sites in Chile
- Volunteers
- 271 people, healthy volunteers welcome
- Sponsor
- Grünenthal GmbH
Infertility
Progesterone Serum Levels in Subfertile Female Patients Undergoing in Vitro Fertilisation (IVF)
This study is aimed to demonstrate that highly purified Menotrophin produces significant lower progesterone serum levels during the follicular phase in comparison to Follitropin alpha in the treatment of subfertile females…
- Trial name
- PREDICT (NCT01225835)
- Testing
- Menotrophin, Follitrophin alpha, Cetrorelix
- Where
- 8 sites in Germany
- Volunteers
- 124 people
- Sponsor
- Ferring Pharmaceuticals
Healthy
Effect of Antidepressants on Sex Hormone Levels and Sexual Functioning
This study will evaluate the effect of antidepressants on sex hormone levels in women and if the potential changes in sex hormone levels are related to sexual side effects.
- Trial name
- NCT00611975
- Testing
- Fluoxetine, Bupropion
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University